Table 1 |
|||
| Personal and clinical data of patients (n = 49) and controls (n = 20) | |||
| Patients | Controls | p | |
| No. (%) or median (IQR)* | No. (%) or median (IQR)* | ||
| Male | 40 (81.6) | 16 (80) | 0.87 |
| Age, y* | 49 (43–55) | 48.5 (44–54) | 0.88 |
| Education, y* | 13 (8.5–17) | 13 (11.3–14.6) | 0.85 |
| Pathological Zung depression scale | 5 (10.3) | ||
| Transmission risk factor: | |||
| Heterosexual | 15 (30.6) | ||
| Injecting drug users | 7 (14.3) | ||
| Homosexual | 20 (40.8) | ||
| Unknown | 7 (14.3) | ||
| Time from HIV diagnosis, y* | 14 (3.5–18.1) | ||
| HCV co-infection | 9 (18.4) | ||
| Past AIDS-defining events | 9 (18.4) | ||
| Past suboptimal therapy | 19 (38.8) | ||
| Off Therapy | 3 (6.1) | ||
| Time from starting last cART regimen, y* | 1.6 (1.1 – 3.1) | ||
| Time from starting first cART regimen, y* | 10.2 (3.1 – 14.6) | ||
| CPE rank* | 6 (4–7) | ||
| HIV-RNA < 50 copies/mL | 44 (89.8) | ||
| CD4 cell count, cells/μL* | 570 (437–734) | ||
| CD4 cell count nadir, cells/μL* | 211 (115–314) | ||
Abbreviations: No: number; IQR: interquartile range; y: years; cART: combined antiretroviral therapy; CPE: penetration effectiveness score; HCV: hepatitis C virus.
Baldonero et al. BMC Psychology 2013 1:3 doi:10.1186/2050-7283-1-3
